JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raucy, J.
Right arrow Articles by Allen, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raucy, J.
Right arrow Articles by Allen, S. W.

Vol. 303, Issue 1, 412-423, October 2002

A Cell-Based Reporter Gene Assay for Determining Induction of CYP3A4 in a High-Volume System

Judy Raucy, Lyndon Warfe, Mei-Fei Yueh and Scott W. Allen

Puracyp, Inc., San Diego, California

Assessing the inducibility of CYP3A4 by various xenobiotics can predict potential drug interactions. In the present investigation, human hepatoma cells were stably integrated with either the CYP3A4 enhancer region and a luciferase reporter gene or the CYP3A4-luciferase construct and the human pregnane X receptor (PXR). Several colonies containing one to three copies of luciferase per cell were identified by Southern blot analysis. Those transformants producing high luciferase activity in response to rifampicin were used to standardize a 96-well plate screening system with minimal inter- and intraplate variability. Standardization also consisted of assessing viability of cells cultured in medium containing various serum concentrations. In cells maintained for 48 h in medium with less than 5% serum, a significant (p < 0.01) decline was observed in viability accompanied by altered induction. A defined serum-free medium also produced less viable cells but did not alter the inductive response. Treatment of transformants with various concentrations of rifampicin produced a dose-response curve with maximal induction at 10 µM (5.6 ± 0.18- and 2.1 ± 0.3-fold above dimethyl sulfoxide (DMSO)-treated cells in transformants with and without PXR, respectively). Of additional agents examined for their ability to induce CYP3A4, omeprazole (200 µM) was the most potent inducer (12.8 ± 1.9- and 2.4 ± 0.2-fold above DMSO-treated cells in transformants with and without PXR, respectively). Mifepristone and mevastatin produced modest induction (~3-fold) in the cell line containing exogenous PXR, but produced less than 1.2-fold increases in cells lacking PXR. Thus, only potent inducers can be identified in the cell line without PXR. In contrast, cells containing the receptor can be used to rank CYP3A4 induction. Because a high volume of chemicals can be readily and accurately screened for their ability to induce CYP3A4 with this format, such a system could be valuable in the initial stages of preclinical drug development.

0022-3565/02/3031-0412$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cheung and F. J. Gonzalez
Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 288 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Surapureddi, R. Rana, J. K. Reddy, and J. A. Goldstein
Nuclear Receptor Coactivator 6 Mediates the Synergistic Activation of Human Cytochrome P-450 2C9 by the Constitutive Androstane Receptor and Hepatic Nuclear Factor-4{alpha}
Mol. Pharmacol., September 1, 2008; 74(3): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
W. Wang, W. W. Prosise, J. Chen, S. S. Taremi, H. V. Le, V. Madison, X. Cui, A. Thomas, K.-C. Cheng, and C. A. Lesburg
Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability
Protein Eng. Des. Sel., July 1, 2008; 21(7): 425 - 433.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N. P. Akentieva, A. S. Evers, D. F. Covey, M. A. Ostuni, et al.
Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 709 - 720.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. L. Urquhart, R. G. Tirona, and R. B. Kim
Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs
J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Ma, Y. Shah, C. Cheung, G. L. Guo, L. Feigenbaum, K. W. Krausz, J. R. Idle, and F. J. Gonzalez
The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A
Drug Metab. Dispos., February 1, 2007; 35(2): 194 - 200.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. R. Faucette, T.-C. Zhang, R. Moore, T. Sueyoshi, C. J. Omiecinski, E. L. LeCluyse, M. Negishi, and H. Wang
Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 72 - 80.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
R. M. Katso, J. H. Parham, M. Caivano, W. C. Clay, J. P. Condreay, D. W. Gray, K. M. Lindley, S. J. Mason, J. Rieger, N. C. Wakes, et al.
Evaluation of Cell-Based Assays for Steroid Nuclear Receptors Delivered by Recombinant Baculoviruses
J Biomol Screen, October 1, 2005; 10(7): 715 - 724.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
M.-F. Yueh, M. Kawahara, and J. Raucy
HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINE
Drug Metab. Dispos., January 1, 2005; 33(1): 38 - 48.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. M. Rosenfeld, R. Vargas Jr., W. Xie, and R. M. Evans
Genetic Profiling Defines the Xenobiotic Gene Network Controlled by the Nuclear Receptor Pregnane X Receptor
Mol. Endocrinol., July 1, 2003; 17(7): 1268 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. L. Raucy
Regulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural Products
Drug Metab. Dispos., May 1, 2003; 31(5): 533 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al.
Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes
Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.